BiotechTube

ZULRESSO®

ApprovedCompleted
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Postpartum Depression

Conditions

Postpartum Depression

Trial Timeline

Oct 8, 2021 → Jul 14, 2022

NCT ID
NCT05059600

About ZULRESSO®

ZULRESSO® is a approved stage product being developed by Supernus Pharmaceuticals for Postpartum Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT05059600. Target conditions include Postpartum Depression.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05059600ApprovedCompleted

Competing Products

20 competing products in Postpartum Depression

See all competitors
ProductCompanyStageHype Score
Misoprostol + OxytocinCiplaPhase 3
77
QuetiapineAstraZenecaPhase 2
52
Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved
85
Eptacog alfa (NovoSeven)Novo NordiskApproved
84
Eptacog alfa (activated)Novo NordiskPre-clinical
22
aripiprazoleBristol Myers SquibbPhase 3
76
fibrinogen concentrate + PlaceboCSLPhase 1/2
40
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg CapsulesBiogenPhase 3
74
SAGE-217 + PlaceboBiogenPhase 3
74
ZuranoloneBiogenPre-clinical
20
ZuranoloneBiogenPre-clinical
20
LPCN 1154A + PlaceboLipocinePhase 3
69
Goserelin 3.6 mg implant + PlaceboBrain BiotechPre-clinical
15
ZULRESSO (brexanolone) injectionSupernus PharmaceuticalsPre-clinical
18
Placebo + SAGE-547 90 μg/kg/hSupernus PharmaceuticalsPhase 3
72
SAGE-547Supernus PharmaceuticalsPhase 2
47
Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/hSupernus PharmaceuticalsPhase 3
72
SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 2
47
GH001GH ResearchPhase 2
47
BrexanoloneBrain BiotechPre-clinical
15

Other Products from Supernus Pharmaceuticals

APOKYNApproved
80
SPN-812Approved
80
SPN-812Approved
80
100mg SPN-812 + PlaceboApproved
80
SPN-538 + PlaceboApproved
80